36 results about "Hepatitis B virus surface" patented technology

The invention relates to application of B-ring ethyoxyl flavanonol in preparing medicaments for treating hepatitis B viruses, in particular to application of a compound as shown in a formula (1) or a medicinal salt thereof in preparing medicaments for clearing away hepatitis B virus surface antigens (HBsAg) and hepatitis B e-antigen (HBeAg) and medicaments for inhibiting the duplication of hepatitis B virus desoxyribonucleic acid (HBV DNA). The compound or the medicinal salt thereof has extremely obvious activity on inhibiting the HBsAg and the HBeAg, and in the presence of a concentration of 20 microgram/milliliter, the intensities for clearing away the HBsAg and the HBeAg of the compound or the medicinal salt thereof are respectively 99.8 percent and 48.5 percent and are 6.2 times and 2.7 times of that of alpha-interferon which is a positive control medicament. More importantly, in the presence of the concentration, the inhibition ratio of the compound or the medicinal salt thereof to the HBV DNA is 64.7 percent, and the activity is 1.7 times of that of the alpha-interferon. Accordingly, the flavone lignan or the medicinal salt thereof can be expected to be used for preparing non-nucleoside medicaments for treating infectious diseases of the hepatitis B viruses.

The invention relates to peptides derived from HBV L protein for the prevention and treatment of Hepatitis B virus (HBV) infection, screening method for removing antigenicity of these peptides and the deantigenic derivative peptide screened through the method, wherein the HBV surface L protein pre-S1 region contains key amino acid sequence of the virus adhesion cell surface acceptor and antigenic amino acid sequence bonding with the anti-L protein antibody. The polypeptides at the HBV surface L protein pre-S1 region can suppress HBV infection to cells. The invention also provides the screening method for removing the antigenicity of these polypeptides.

The invention relates to a nanometer magnetic particle chemiluminiscence kit, a preparation method and a detection method of a hepatitis B virus surface-antibody. The kit comprises a solution containing hepatitis B virus surface-antibody marked by fluorescein, a suspension liquid of the magnetic particle coated with a fluorescein antibody and a solution containing the hepatitis B virus surface-antibody marked by alkaline phosphatase. According to the invention, quantitative detection of the hepatitis B virus surface-antibody can carried out at lower cost, higher accuracy and higher precision.

The invention discloses a kit and a method for detecting hepatitis B virus surface antigen (HBsAg). The detection kit is used for marking hepatitis B virus surface antibody (HBsAb) by using metalloporphyrin obtained by using water-soluble A3B type metalloporphyrin to mark the HBsAb. The detection kit and the detection method have the advantages that: (1) free metalloporphyrin molecules are separated from a coupled substance easily after an A3B type metalloporphyrin complex is coupled with the HBsAb to obtain a high-purity labelled antibody, so that non-specific adsorption background signals are reduced when the HBsAg is detected by chemical luminescence immunodetection, and detection sensitivity is greatly improved; (2) the method is simple, convenient and quick; automation is realized easily; and specificity of immunoreaction, high sensitivity of chemical luminescence reaction and stability of a chemical marker are achieved; and (3) a new method is provided for detecting the HBsAg quickly and accurately, and preventing and treating the hepatitis B virus.

The present invention is a composition that comprises at least two hepatitis B virus surface antigens (HBsAgs), fragments thereof and/or nucleic acids encoding them, the HBsAgs differing in HBV genotype in the S region and/or pre-S1 region and the composition containing no HBV core antigen (HBcAg) or nucleic acid encoding that antigen. The present invention also includes pharmaceutical compositions, especially vaccines, comprising these compositions for the prevention and/or treatment of an HBV infection or an HBV-mediated disease. The present invention further includes a method of preparing a patient-specific medicament for the therapeutic treatment of hepatitis B.

An application of staphylococcal enterotoxin A gene and its coding protein in obviously improving the responsiveness of animal to DNA vaccine and intensifying the immunogenicity of various DNA vaccines for hepatitis B virus, malaria, etc is disclosed.

The present invention relates to diagnostic reagents for antibody against hepatitis B surface antigen and for antibody against hepatitis B virus using a sandwich immunoassay as a quantitative or qualitative analysis method for antibody against hepatitis B surface antigen and for antibody against hepatitis B virus, characterized in that each diagnostic reagent comprises a pair of hepatitis B surface antigens which are different each other and composed of primary antigen immobilized on a solid support and secondary antigen conjugated to a marker. Also, the present invention relates to preparation methods thereof. Further, the present invention relates to diagnostic methods for antibody against hepatitis B surface antigen and for antibody against hepatitis B virus. In accordance with the present invention, there are provided diagnostic reagents and methods with markedly enhanced sensitivity and specificity in comparison to diagnostic reagents and methods in which single kind of hepatitis B virus surface antigens are used.

The invention discloses an extrasin alpha original gene new usage, which is characterized by the following: the ProT alpha improves the reactivity of animal reacting to DNA vaccin observably, which can use as immune original-nature reinforcing adjuvant of DNA vaccin; the extrasin alpha original gene strengthens immune original-nature of hepatitis B virus surface antigen DNA vaccin, malarial disease multiple-epitope antigen DNA vaccin and kinds of DNA vaccines, which possesses broad-spectrum nature.

The invention relates to a hepatitis B virus surface protein mutant, in particular, relates to an S protein mutant which can inhibit hepatitis B virus (HBV) replication and/or inhibit surface antigen (HBsAg) expression and secretion, and further relates to a biological material related to the S protein mutant and an application of the S protein mutant in HBV resistance. In-vitro tests show that an S-L13R/E/D/K mutant can be used for inhibiting the replication of HBV in Huh7 cells and inhibiting the expression and secretion of HBsAg; in an Adv/prcccDNA hepatitis B chronic mouse model, blood HBsAg is converted into negative, surface antibody HBsAb can appear in blood, HBeAg level and HBV DNA level in serum are also converted into negative, and no obvious ALT rise is caused in the negative conversion process, so that the safety of the antibody is proved, the S protein mutant has obvious influence on the secretion of HBsAg of different genotypes of HBV, and the S protein mutant of different genotypes has obvious influence on the secretion of HBsAg of the same genotype of HBV, so that a new method is provided for clinically treating chronic hepatitis B.

The invention relates to application of substituted silybin ester in preparing a medicament for treating virus hepatitis B, in particular to application of 23-position ethyl-malonyl substituted silybin ester or medicinal salt thereof in preparing a medicament for reducing hepatitis B virus surface antigen HBsAg, inhibiting HBV DNA replication and treating hepatitis B virus infected diseases. The flavonolignan has remarkable effect of inhibiting HBsAg activity, and the strength of the flavonolignan at the concentration of 100 micrograms per milliliter for clearing the HBsAg is two times and half that of a positive control medicament alpha-interferon; and meanwhile, the compound has strong inhibiting activity on the HBV DNA. Pharmacodynamical results show that the flavonolignan or the medicinal salt thereof can be expected to be used for preparing the medicament for reducing hepatitis B virus surface antigen, inhibiting HBV DNA replication and treating the hepatitis B virus infected diseases.

The invention discloses a new use of staphylococcal enterotoxin gene A. An experiment carried out by the author of the invention shows that the staphylococcal enterotoxin gene A can obviously improve the reactivity of animals to DNA vaccines and can be used as an adjuvant for improving the immunogenicity of the DNA vaccines or recombinant subunit vaccines. The staphylococcal enterotoxin gene A can improve the immunogenicity of various DNA vaccines, such as HBV surface antigen DNA vaccine and malaria multi-epitope antigen DNA vaccine, etc., has broad spectrum, and is a rare adjuvant for improving the immunogenicity of the DNA vaccines. Therefore, the staphylococcal enterotoxin gene A has great significance in the production and the application of the DAN vaccines and the recombinant subunit vaccines.

The invention discloses a humanized single chain antibody of anti-hepatitis B virus surface antigen a determinant, the amino acid sequence thereof is SEQ ID NO: 1. The VH amino acid sequence of the antibody is SEQ ID NO: 2, and the VL amino acid sequence of the antibody is SEQ ID NO: 3. The humanized single chain antibody of the anti-hepatitis B virus surface antigen a determinant is used for preparing preventive passive immunity drug or preparing medicines for treating chronic viral hepatitis B.